FDA Panel Greenlights mRNA Flu Vaccine for Older Adults: A Major Step Forward

The FDA advisory panel has voted unanimously to recommend Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and over, marking a significant advancement in vaccine technology and public health strategy.